Literature DB >> 11454899

Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery.

L P Dwoskin1, P A Crooks.   

Abstract

Neuronal nicotinic acetylcholine receptors are distributed extensively throughout the central and peripheral nervous systems. Currently, there is great interest in determining the structural and functional diversity of these receptors, and in developing subtype-selective agonists that have potential as therapeutic agents for neuropathology and disease. However, relatively little attention has been focused on the development of subtype-selective nicotinic receptor antagonists. Such antagonists would be beneficial for establishing the role of specific nicotinic receptor subtypes in physiological function and for unraveling the complexities of neuronal nicotinic receptor function. Furthermore, these subtype-selective antagonists may also prove to be beneficial in the treatment of neuropathology and disease. The current perspective summarizes the research that has been carried out with both classical competitive antagonists and more recently developed competitive nicotinic receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454899

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

2.  Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery.

Authors:  Tatiana F González-Cestari; Brandon J Henderson; Ryan E Pavlovicz; Susan B McKay; Raed A El-Hajj; Aravinda B Pulipaka; Crina M Orac; Damon D Reed; R Thomas Boyd; Michael X Zhu; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

3.  Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells.

Authors:  Nagendra S Singh; Rajib K Paul; Anuradha Ramamoorthy; Marc C Torjman; Ruin Moaddel; Michel Bernier; Irving W Wainer
Journal:  Cell Signal       Date:  2013-09-04       Impact factor: 4.315

4.  Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.

Authors:  Vinay Parikh; Jinzhao Ji; Michael W Decker; Martin Sarter
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

5.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

Review 6.  Interoception and learning: import to understanding and treating diseases and psychopathologies.

Authors:  Rick A Bevins; Joyce Besheer
Journal:  ACS Chem Neurosci       Date:  2014-07-22       Impact factor: 4.418

7.  Characterization of the circuits that generate spontaneous episodes of activity in the early embryonic mouse spinal cord.

Authors:  M Gartz Hanson; Lynn T Landmesser
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

8.  Inhibition of native and recombinant nicotinic acetylcholine receptors by the myristoylated alanine-rich C kinase substrate peptide.

Authors:  Elaine A Gay; Rebecca C Klein; Mark A Melton; Perry J Blackshear; Jerrel L Yakel
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

9.  Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-09-26       Impact factor: 2.823

10.  Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.

Authors:  Werner J Geldenhuys; Vamshi K Manda; Rajendar K Mittapalli; Cornelis J Van der Schyf; Peter A Crooks; Linda P Dwoskin; David D Allen; Paul R Lockman
Journal:  Bioorg Med Chem Lett       Date:  2009-12-28       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.